When is indefinite warfarin therapy indicated in the treatment of antithrombin III (ATIII) deficiency?

Updated: Mar 04, 2020
  • Author: James L Harper, MD; Chief Editor: Hassan M Yaish, MD  more...
  • Print

Antithrombin III–deficient patients with heterozygotic mutations who experience a second clot, particularly in mesenteric or splanchnic beds, are at significant risk of further life-threatening or organ-threatening thrombosis. These patients are candidates for indefinite warfarin therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!